| The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor. | None |
| The MET oncogene drives a genetic programme linking cancer to haemostasis. | None |
| negative feedback regulation in which Met activation leads to transcriptional induction of Notch function, which in turn limits HGF activity through repression of the Met oncogene | None |
| Localization of the 5 end of the MCF2 oncogene to human chromosome 15q15----q23. | None |
| These results suggest that CD151 forms a structural and functional complex with c-Met and integrin alpha3/alpha6, and exerts its oncogenic functions through excessive activation of the HGF/c-Met signalling pathway. | None |
| Oncogenic Met receptor induces cell-cycle progression in Xenopus oocytes independent of direct Grb2 and Shc binding or Mos synthesis, but requires phosphatidylinositol 3-kinase and Raf signaling. | None |
| Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene. | None |
| Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor). | None |
| Gab1 is required for cell cycle transition, cell proliferation, and transformation induced by an oncogenic met receptor. | None |
| Mimp expression reduces hepatocyte growth factor/scatter factor-induced proliferation and scattering by attenuating and altering the downstream signaling of met proto-oncogene. | None |
| tpr-met oncogene product induces maturation-producing factor activation in Xenopus oocytes. | None |
| Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. | None |
| Silencing the MET oncogene leads to regression of experimental tumors and metastases. | None |
| persistent expression of the MET oncogene is mandatory until the advanced phases of cancer progression. | None |
| Signaling networks assembled by oncogenic EGFR and c-Met. | None |
| oncogenic EGFR and c-Met have roles in pathways mediating drug response | None |
| Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. | None |
| MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). | None |
| the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2) are regulated by MicroRNA miR-199a* | None |
| Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. | None |